NVision Quantum Expands POLARIS Platform with RESQ Project Funding

€2.5 million in Horizon Europe funding will accelerate the development of NVision Quantum Technologies’ POLARIS platform and establish a new metabolic imaging research center at Yonsei University in South Korea. The three-year RESQ project aims to improve image resolution and sensitivity for detecting brain metastases, a challenge impacting roughly one in five cancer patients. This expansion marks NVision’s entry into the Asian market and builds upon existing POLARIS deployments in Europe and the United States. “Our POLARIS platform is already deployed at leading institutions across Europe and the United States, and we are continuing to expand both the capabilities and international reach of the platform,” said Dr. Sella Brosh, CEO and Co-Founder of NVision Quantum Technologies. The project anticipates POLARIS installation at Yonsei University in early 2027.

The €2.5 million Horizon Europe funding secured for the RESQ project signals substantial investment in advancing metabolic imaging capabilities and establishing a new research platform. The consortium, comprised of NVision, Yonsei University, Ulm University, and Tesla Dynamic Coils, aims to develop a higher-resolution imaging workflow specifically for brain metastases research. Brain metastases affect approximately one in five cancer patients and present a difficult diagnostic challenge; standard MRI often fails to capture the crucial metabolic activity indicative of disease progression or treatment response. RESQ directly addresses this limitation by leveraging POLARIS to improve image resolution and sensitivity, enabling visualization of tumor metabolism at a finer scale. Yonsei University will biologically validate the workflow using preclinical models, while Ulm University focuses on quantum-optimized imaging methods to maximize signal efficiency. Tesla Dynamic Coils will engineer specialized MRI hardware to further enhance resolution.

While conventional magnetic resonance imaging (MRI) can identify tumor size and location, it struggles to reveal crucial metabolic activity, hindering effective treatment monitoring. Researchers are now focused on hyperpolarized MRI, a technique visualizing tumor metabolism in real-time, but its application to the typically small and subtly changing metastases requires substantial improvements in image resolution and sensitivity. A new €2.5 million investment will support the consortium, including Ulm University and Tesla Dynamic Coils, in doubling the spatial resolution of hyperpolarized MRI while maximizing signal quality. “RESQ advances POLARIS for one of the most demanding applications in medical imaging and creates the foundation for our long-term presence in South Korea,” added Dr. Brosh. This collaborative effort seeks to visualize tumor metabolism with increased detail, potentially revolutionizing the detection and monitoring of brain metastases.

NVision Quantum Technologies is leading an effort to refine metabolic imaging of brain metastases through quantum enhancement. This investment will not only advance NVision’s POLARIS platform but also establish a dedicated research platform at Yonsei University in South Korea, marking a significant expansion into the Asian market. This technique visualizes tumor metabolism in real-time, but detecting lesions as small as a few millimeters requires exceptional image clarity. NVision’s POLARIS platform utilizes quantum-enhanced hyperpolarization to amplify the MRI signal of metabolic imaging agents, allowing for real-time observation on standard systems. Tesla Dynamic Coils is engineering specialized RF hardware to further enhance resolution and sensitivity, aiming for a robust and reproducible technology applicable beyond the project’s scope. The anticipated POLARIS deployment at Yonsei University in early 2027 will establish a new infrastructure for metabolic brain imaging research.